Search by Drug Name or NDC
NDC 72241-0032-04 Nebivolol 2.5 mg/1 Details
Nebivolol 2.5 mg/1
Nebivolol is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Modavar Pharmaceuticals LLC. The primary component is NEBIVOLOL HYDROCHLORIDE.
MedlinePlus Drug Summary
Nebivolol is used alone or in combination with other medications to treat high blood pressure. Nebivolol is in a class of medications called beta blockers. It works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 72241-0032-04Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Nebivolol
Product Information
| NDC | 72241-0032 |
|---|---|
| Product ID | 72241-032_53d2f49b-b0b8-46fc-b80d-1ac3756e7e7c |
| Associated GPIs | 33200040100310 |
| GCN Sequence Number | 063510 |
| GCN Sequence Number Description | nebivolol HCl TABLET 2.5 MG ORAL |
| HIC3 | J7C |
| HIC3 Description | BETA-ADRENERGIC BLOCKING AGENTS |
| GCN | 99235 |
| HICL Sequence Number | 016740 |
| HICL Sequence Number Description | NEBIVOLOL HCL |
| Brand/Generic | Generic |
| Proprietary Name | Nebivolol |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Nebivolol |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 2.5 |
| Active Ingredient Units | mg/1 |
| Substance Name | NEBIVOLOL HYDROCHLORIDE |
| Labeler Name | Modavar Pharmaceuticals LLC |
| Pharmaceutical Class | Adrenergic beta-Antagonists [MoA], beta-Adrenergic Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA208717 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72241-0032-04 (72241003204)
| NDC Package Code | 72241-032-04 |
|---|---|
| Billing NDC | 72241003204 |
| Package | 90 TABLET in 1 BOTTLE (72241-032-04) |
| Marketing Start Date | 2021-12-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |